P4818Role of new oral anticoagulants in left atrial occluder device implants
نویسندگان
چکیده
منابع مشابه
Transesophageal echocardiographic diagnosis of left atrial appendage occluder device infection.
The safety and efficacy of a left atrial appendage closure device is currently under evaluation in a large-scale multi-center clinical trial. We report an initial case of left atrial appendage occluder device infection with Staphylococcus aureus; transesophageal echocardiography played a pivotal role in diagnosis and treatment.
متن کاملNew oral anticoagulants in atrial fibrillation forever?
A trial fibrillation is the most common chronic cardiac arrhythmia in clinical cardiology. It affects ≈1% of the population, and, of individuals >80 years of age, ≈10% have this rhythm disturbance. Owing to the loss of the atrial contribution to ventricular filling, left ventricular function is diminished resulting in a propensity to heart failure, fatigue, and disability. Furthermore, the sens...
متن کاملNew oral anticoagulants in atrial fibrillation.
Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet inhibitor) and vitamin K antagonists (VKAs; oral anticoagulants), including warfarin, are the only approved antithrombotic therapies for stroke prevention in patients with AF. Although effective, VKAs have unpredictable pharmacological effects, requiring regular coagulation monitoring and dos...
متن کاملPreclinical evaluation of a new left atrial appendage occluder (Lifetech LAmbre™ device) in a canine model.
OBJECTIVES The study evaluated the feasibility and safety of a novel left atrial appendage (LAA) occluder (LAmbre™, Lifetech Scientific Corp., China) in canines. BACKGROUND Transcatheter LAA occlusion is comparable to warfarin in preventing atrial fibrillation-related strokes. METHODS Twenty-two healthy dogs (28 ± 3 kg) received LAmbre implants. The device is delivered by an 8-10 French she...
متن کاملNew oral anticoagulants for atrial fibrillation.
Case 1A: A 68-year-old man with a past medical history of atrial fibrillation (AF), hypertension, and type 2 diabetes mellitus has been on anticoagulation therapy with warfarin for 6 years. The patient’s target international normalized ratio (INR) is 2.0 to 3.0. The patient has been managed by a pharmacist-run anticoagulation clinic, and his recent warfarin doses and INR values are shown in Tab...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal
سال: 2018
ISSN: 0195-668X,1522-9645
DOI: 10.1093/eurheartj/ehy563.p4818